These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28146430)

  • 1. Intratumoral heterogeneity of intrahepatic cholangiocarcinoma.
    Walter D; Döring C; Feldhahn M; Battke F; Hartmann S; Winkelmann R; Schneider M; Bankov K; Schnitzbauer A; Zeuzem S; Hansmann ML; Peveling-Oberhag J
    Oncotarget; 2017 Feb; 8(9):14957-14968. PubMed ID: 28146430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
    Dong LQ; Shi Y; Ma LJ; Yang LX; Wang XY; Zhang S; Wang ZC; Duan M; Zhang Z; Liu LZ; Zheng BH; Ding ZB; Ke AW; Gao DM; Yuan K; Zhou J; Fan J; Xi R; Gao Q
    J Hepatol; 2018 Jul; 69(1):89-98. PubMed ID: 29551704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
    Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
    BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations.
    Kim YH; Hong EK; Kong SY; Han SS; Kim SH; Rhee JK; Hwang SK; Park SJ; Kim TM
    Oncotarget; 2016 Apr; 7(17):23825-36. PubMed ID: 27009864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrative analysis reveals different feature of intrahepatic cholangiocarcinoma subtypes.
    Chen Z; Gao J; Li Z; Ma D; Wang Y; Cheng Q; Zhu J; Li Z
    Liver Int; 2024 Sep; 44(9):2477-2493. PubMed ID: 38924592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
    Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
    Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent Mutations in APC and CTNNB1 and Activated Wnt/β-catenin Signaling in Intraductal Papillary Neoplasms of the Bile Duct: A Whole Exome Sequencing Study.
    Fujikura K; Akita M; Ajiki T; Fukumoto T; Itoh T; Zen Y
    Am J Surg Pathol; 2018 Dec; 42(12):1674-1685. PubMed ID: 30212390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
    J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay.
    Arnold A; Bahra M; Lenze D; Bradtmöller M; Guse K; Gehlhaar C; Bläker H; Heppner FL; Koch A
    Exp Mol Pathol; 2015 Oct; 99(2):344-53. PubMed ID: 26260902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing.
    Putra J; de Abreu FB; Peterson JD; Pipas JM; Mody K; Amos CI; Tsongalis GJ; Suriawinata AA
    Exp Mol Pathol; 2015 Oct; 99(2):240-4. PubMed ID: 26189129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Geospatial Immune Heterogeneity Reflects the Diverse Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma.
    Lin Y; Peng L; Dong L; Liu D; Ma J; Lin J; Chen X; Lin P; Song G; Zhang M; Liu Y; Rao J; Wei C; Lu Y; Zhang S; Ding G; Peng Z; Lu H; Wang X; Zhou J; Fan J; Wu K; Gao Q
    Cancer Discov; 2022 Oct; 12(10):2350-2371. PubMed ID: 35853232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers.
    Liao H; Chen X; Wang H; Lin Y; Chen L; Yuan K; Liao M; Jiang H; Peng J; Wu Z; Huang J; Li J; Zeng Y
    Cancer Res; 2024 Jun; 84(11):1747-1763. PubMed ID: 38471085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
    Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
    Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.
    Zhu AX; Borger DR; Kim Y; Cosgrove D; Ejaz A; Alexandrescu S; Groeschl RT; Deshpande V; Lindberg JM; Ferrone C; Sempoux C; Yau T; Poon R; Popescu I; Bauer TW; Gamblin TC; Gigot JF; Anders RA; Pawlik TM
    Ann Surg Oncol; 2014 Nov; 21(12):3827-34. PubMed ID: 24889489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma During Targeted Therapy.
    González-Medina A; Vila-Casadesús M; Gomez-Rey M; Fabregat-Franco C; Sierra A; Tian TV; Castet F; Castillo G; Matito J; Martinez P; Miquel JM; Nuciforo P; Pérez-López R; Macarulla T; Vivancos A
    Clin Cancer Res; 2024 Oct; 30(19):4491-4504. PubMed ID: 39078735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma.
    Xu S; Guo Y; Zeng Y; Song Z; Zhu X; Fan N; Zhang Z; Ren G; Zang Y; Rao W
    BMC Cancer; 2021 Feb; 21(1):152. PubMed ID: 33579226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic profiling of multifocal intrahepatic cholangiocarcinoma reveals intraindividual concordance of genetic alterations.
    Lee SH; Simoneau EB; Karpinets T; Futreal PA; Zhang J; Javle M; Zhang J; Vauthey JN; Lee JS; Estrella JS; Chun YS
    Carcinogenesis; 2021 Apr; 42(3):436-441. PubMed ID: 33200197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers.
    Zhang Y; Ma Z; Li C; Wang C; Jiang W; Chang J; Han S; Lu Z; Shao Z; Wang Y; Wang H; Jiao C; Wang D; Wu X; Shen H; Wang X; Hu Z; Li X
    Nat Commun; 2022 Jun; 13(1):3061. PubMed ID: 35650238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.
    Sia D; Losic B; Moeini A; Cabellos L; Hao K; Revill K; Bonal D; Miltiadous O; Zhang Z; Hoshida Y; Cornella H; Castillo-Martin M; Pinyol R; Kasai Y; Roayaie S; Thung SN; Fuster J; Schwartz ME; Waxman S; Cordon-Cardo C; Schadt E; Mazzaferro V; Llovet JM
    Nat Commun; 2015 Jan; 6():6087. PubMed ID: 25608663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.